MarketCapExport financials
10x Genomics (TXG)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
10x Genomics Financial Ratios 2025-2011 | TXG
Brief overview of 10x Genomics's market valuation
Ratios are assessed across five available annual reports in the 2021–2025 interval.
The current valuation set is P/S 4.11x (median 9.12x), P/B 3.32x (median 7.42x). Multiples are on average 55.1% below their own medians. Shares look cheaper than their recent historical valuation.
The latest available business-quality ratios are ROE -5.5%, ROA -4.2%, ROCE -7.7%. Negative returns point to losses or poor capital efficiency. Valuation multiples are less informative in this setting.
The time from paying for inputs to receiving cash fell from 217.9 days to 142.7 days. Cash turnover improved.
Valuation takeaway
10x Genomics trades below its own history, but weak profitability may explain the discount. Low multiples alone do not prove undervaluation.
Annual Financial Ratios 10x Genomics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-60.7 | -14.0 | -22.1 | -36.0 | -154.4 | -33.2 | -117.0 | - | -56.2 | - | - | - | - | - | - |
P/S |
4.1 | 4.2 | 9.1 | 11.6 | 18.3 | 60.2 | 14.9 | - | 14.8 | - | - | - | - | - | - |
EPS |
-0.3 | -1.5 | -2.2 | -1.5 | -0.5 | -5.4 | -0.8 | -8.4 | -1.6 | - | - | - | - | - | - |
EV (Enterprise Value) |
2.42 B | 2.42 B | 5.51 B | 5.98 B | 8.6 B | 17.5 B | 3.42 B | 279 M | 1.2 B | - | - | - | - | - | - |
EBITDA per Share |
-0.2 | -1.32 | -1.96 | -1.25 | -0.28 | -5.14 | -0.601 | - | -0.17 | - | - | - | - | - | - |
EV/EBITDA |
-97.5 | -15.2 | -24.0 | -41.9 | -274.4 | -31.4 | -138.8 | - | -72.0 | - | - | - | - | - | - |
PEG |
-1.59 | -0.07 | - | - | - | 0.06 | -2.61 | - | 149.18 | - | - | - | - | - | - |
P/B |
3.3 | 3.6 | 7.6 | 7.4 | 11.0 | 24.4 | 8.7 | - | -9.4 | - | - | - | - | - | - |
P/CF |
19.4 | 383.2 | -371.4 | -177.8 | -420.6 | -82.6 | -449.3 | - | -73.0 | - | - | - | - | - | - |
ROE % |
-5.47 | -25.72 | -34.42 | -20.60 | -7.12 | -73.43 | -7.44 | - | 16.68 | - | - | - | - | - | - |
ROA % |
-4.18 | -19.88 | -26.43 | -16.13 | -5.71 | -58.40 | -5.16 | - | -24.81 | - | - | - | - | - | - |
ROCE % |
-7.66 | -27.40 | -35.80 | -20.84 | -6.39 | -72.27 | -5.63 | - | -34.37 | - | - | - | - | - | - |
Current Ratio |
4.2 | 4.4 | 4.3 | 4.6 | 5.1 | 4.9 | 7.6 | - | 3.1 | - | - | - | - | - | - |
DSO |
38.3 | 60.6 | 64.6 | 67.0 | 50.8 | 51.7 | 49.5 | - | 68.5 | - | - | - | - | - | - |
DIO |
127.9 | 145.8 | 135.4 | 214.7 | 221.5 | 141.2 | 91.3 | - | 167.2 | - | - | - | - | - | - |
DPO |
23.5 | 26.6 | 32.5 | 59.0 | 54.3 | 55.4 | 77.9 | - | 188.1 | - | - | - | - | - | - |
Operating Cycle |
166.2 | 206.3 | 200.0 | 281.6 | 272.3 | 192.8 | 140.9 | - | 235.7 | - | - | - | - | - | - |
Cash Conversion Cycle |
142.7 | 179.7 | 167.4 | 222.6 | 217.9 | 137.5 | 62.9 | - | 47.6 | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios 10x Genomics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.1 | -0.22 | 0.28 | -0.28 | -0.3 | -0.32 | -0.5 | -0.79 | -0.53 | -0.44 | - | - | -0.57 | -0.38 | - | -0.15 | -0.1 | -0.11 | - | -0.65 | -0.41 | -0.22 | -0.07 | -0.33 | -0.7 | -0.25 | -5.4 | -1.13 | -0.45 | -1.23 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
-0.06 | -0.05 | 0.37 | -0.26 | - | - | -0.44 | - | - | -0.39 | - | - | -0.44 | -0.31 | - | -0.14 | -0.01 | -0.05 | - | -0.54 | -0.33 | -0.17 | - | -0.17 | -0.53 | -0.14 | - | -0.88 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-5.55 | -8.84 | -10.57 | -23.38 | -31.00 | -33.92 | -35.01 | -34.90 | -27.68 | -21.95 | -15.63 | -15.63 | -17.04 | -10.35 | -5.09 | -14.00 | -17.29 | -18.74 | -17.21 | -18.90 | -12.28 | -9.43 | -7.44 | 28.59 | 37.85 | 44.91 | 58.11 | 6.98 | 4.47 | 12.33 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-4.28 | -6.77 | -8.17 | -18.19 | -19.39 | -22.01 | -22.16 | -15.67 | -15.67 | -17.40 | -12.40 | -12.40 | -13.53 | -8.30 | -4.07 | -11.16 | -13.75 | -14.89 | -13.68 | -14.86 | -9.36 | -6.83 | -5.16 | -64.73 | -75.49 | -0.60 | -60.75 | -12.34 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-7.87 | -11.51 | -13.17 | -25.62 | -32.78 | -35.03 | -35.74 | -35.24 | -27.70 | -21.69 | -15.21 | -15.21 | -16.53 | -9.83 | -4.66 | -13.49 | -16.84 | -18.21 | -16.85 | -19.02 | -12.66 | -8.04 | -5.35 | 1.43 | -2.47 | -0.72 | - | 6.79 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
5.0 | 4.2 | 4.7 | 4.6 | 4.4 | 4.5 | 4.5 | - | - | 4.8 | 4.6 | - | 4.6 | 5.1 | 5.1 | 5.2 | 5.1 | 4.7 | 4.9 | 4.9 | 4.9 | 4.9 | 3.3 | 3.3 | 3.3 | 3.3 | 1.2 | 1.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
25.1 | 28.7 | 27.1 | 40.1 | 52.6 | 54.4 | 29.5 | - | 24.2 | 61.9 | - | - | 60.8 | 64.5 | - | 50.3 | 46.1 | 46.8 | - | 65.1 | 108.9 | 53.7 | 40.5 | 49.8 | 54.5 | 52.3 | 50.7 | 35.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
117.9 | 122.7 | 137.1 | 155.7 | 183.8 | 160.0 | 78.9 | - | 79.5 | 208.4 | - | - | 221.2 | 221.4 | - | 177.2 | 766.7 | 183.1 | - | 189.7 | 272.0 | 136.6 | - | 90.0 | 92.9 | 77.9 | - | 74.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
36.3 | 31.9 | 24.8 | 33.5 | 47.8 | 38.7 | 19.2 | - | 28.3 | 64.7 | - | - | 75.2 | 65.0 | - | 61.8 | 294.8 | 54.3 | - | 29.8 | 42.8 | 53.6 | - | 76.8 | 79.2 | 71.3 | - | 76.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | 236.3 | 214.4 | 211.8 | - | - | 270.3 | - | - | 282.1 | 285.9 | - | 227.5 | 812.8 | 229.9 | - | 254.8 | 380.9 | 190.3 | 40.5 | 139.8 | 147.4 | 130.2 | 50.7 | 109.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | 188.5 | 175.7 | 164.8 | - | - | 205.5 | - | - | 206.8 | 220.9 | - | 165.7 | 518.0 | 175.7 | - | 224.9 | 338.1 | 136.7 | 40.5 | 63.0 | 68.2 | 58.9 | 50.7 | 33.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company 10x Genomics, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Health information services industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
American Well Corporation
AMWL
|
$ 13.97 | 5.91 % | $ 224 M |  USA |
 |
Evolent Health
EVH
|
$ 4.83 | -0.82 % | $ 552 M | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
Omnicell
OMCL
|
$ 36.34 | -0.41 % | $ 1.67 B | USA |
 |
OptimizeRx Corporation
OPRX
|
$ 9.37 | 4.93 % | $ 174 M | USA |
 |
Phreesia
PHR
|
$ 12.26 | 1.78 % | $ 732 M | USA |
 |
GoodRx Holdings
GDRX
|
$ 3.57 | 1.42 % | $ 1.27 B | USA |
 |
Health Catalyst
HCAT
|
$ 1.74 | -0.57 % | $ 122 M | USA |
 |
So-Young International
SY
|
$ 2.19 | -3.1 % | $ 171 M |  China |
 |
Teladoc Health
TDOC
|
$ 6.3 | 1.45 % | $ 1.11 B | USA |
 |
HealthEquity
HQY
|
$ 97.88 | 1.33 % | $ 8.43 B | USA |
 |
Veeva Systems
VEEV
|
$ 320.55 | 0.59 % | $ 52.5 B | USA |
 |
Schrödinger
SDGR
|
$ 23.9 | 2.14 % | $ 1.76 B | USA |
 |
Zhongchao
ZCMD
|
$ 1.34 | -4.96 % | $ 4.58 M | China |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
HealthStream
HSTM
|
$ 33.51 | -0.77 % | $ 1.01 B | USA |
 |
Progyny
PGNY
|
$ 28.44 | -0.49 % | $ 2.42 B | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |
 |
SCWorx Corp.
WORX
|
- | - | $ 7.71 M | USA |